You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-MM therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

HIV Trial in Houston (Aldesleukin)

Completed
  • HIV Infections
  • Houston, Texas
    Thomas Street Clinic C605-020 CRS
Oct 27, 2021

HIV Trial in Bangkok (Aldesleukin, ART)

Completed
  • HIV Infections
  • Bangkok, Ratchathewi, Thailand
  • +1 more
Oct 27, 2021

HIV Trial in London (Aldesleukin)

Completed
  • HIV Infections
  • London, United Kingdom
    Kobler Ctr. of Chelsea Westminster Hosp. C604-030 CRS
Oct 27, 2021

HIV Trial in Ciudad de Buenos Aires (Aldesleukin)

Completed
  • HIV Infections
  • Ciudad de Buenos Aires, Buenos Aires, Argentina
  • +3 more
Oct 27, 2021

HIV Trial in Chicago, Durham, Galveston (Interleukin-12, HIV-1 C4-V3 Polyvalent Peptide Vaccine)

Completed
  • HIV Infections
  • Chicago, Illinois
  • +2 more
Oct 28, 2021

Multiple Myeloma Cells From miRNAs Released From B Cells, and

Recruiting
  • Multiple Myeloma
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
    Nov 23, 2023

    Unspecified Adult Solid Tumor Trial in Los Angeles (Millimeter-Wave Holographic Imaging)

    Withdrawn
    • Unspecified Adult Solid Tumor
    • Millimeter-Wave Holographic Imaging
    • Los Angeles, California
      USC / Norris Comprehensive Cancer Center
    Jan 30, 2023

    Hypertension, Systolic, Cerebrovascular Disease Trial in Farmington (Anti-hypertensive therapy to SBP 130 mm Hg,

    Completed
    Has Results
    • Hypertension, Systolic
    • Cerebrovascular Disease
    • Anti-hypertensive therapy to SBP 130 mm Hg
    • Anti-hypertensive therapy to SBP 145 mm Hg
    • Farmington, Connecticut
      University of Connecticut Health Center
    Oct 29, 2020

    Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

    Not yet recruiting
    • Acute Myeloid Leukemia (AML)
    • Multiple Myeloma (MM)
    • 3x10(6) CART-38 cellls
    • +5 more
    • (no location specified)
    Jul 15, 2022

    Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

    Not yet recruiting
    • Relapsed/ Refractory Multiple Myeloma
    • GC012F
    • (no location specified)
    Apr 28, 2023

    Multiple Myeloma Trial in United States (Daratumumab, Lenalidomide, Bortezomib)

    Recruiting
    • Multiple Myeloma
    • Ann Arbor, Michigan
    • +3 more
    Jan 19, 2023

    Axial Spondyloarthritis Trial in Nîmes, Montpellier, Tours (Daily dietary supplementation with Fibruline, Anti-IL-17 therapy)

    Recruiting
    • Axial Spondyloarthritis
    • Daily dietary supplementation with Fibruline
    • Anti-IL-17 therapy
    • Nîmes, Gard, France
    • +2 more
    Apr 19, 2023

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Therapy of Anti-NMDAR Encephalitis at Diagnosis

    Active, not recruiting
    • Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis
      • Rotterdam, Netherlands
        Erasmus Medical Center
      Sep 4, 2023

      Chronic Musculoskeletal Pain Trial in West Los Angeles, West Haven (Emotional Awareness and Expression Therapy, Mindfulness

      Not yet recruiting
      • Chronic Musculoskeletal Pain
      • Emotional Awareness and Expression Therapy
      • +2 more
      • West Los Angeles, California
      • +1 more
      Aug 16, 2023

      Hiv Trial in Nice (plasma inflammatory markers, CD4/CD8 ratio)

      Not yet recruiting
      • Hiv
      • plasma inflammatory markers
      • CD4/CD8 ratio
      • Nice, France
        CHU Nice
      Jan 16, 2023

      HIV Trial in United States (Indinavir sulfate)

      Completed
      • HIV Infections
      • Indinavir sulfate
      • San Francisco, California
      • +13 more
      Oct 27, 2021

      Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

      Recruiting
      • Acute Myeloid Leukemia Refractory
      • Acute Myeloid Leukemia, in Relapse
      • anti Tim-3/CD123 CAR-T cell therapy
      • Xuzhou, Jiangsu, China
        Kailin Xu
      Nov 4, 2023

      Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)

      Recruiting
      • Multiple Myeloma
      • Human BCMA Targeted T Cells Injection
      • Shanghai, Shanghai, China
      • +1 more
      Dec 7, 2022

      Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

      Recruiting
      • Oral Squamous Cell Carcinoma
      • +3 more
      • Camrelizumab (anti-PD-1 inhibitor)
      • Apatinib (anti-VEGFR inhibitor)
      • Shanghai, Shanghai, China
        Ninth People's Hospital, Shanghai Jiao Tong University School of
      Oct 8, 2022

      Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

      Not yet recruiting
      • Relapsed Refractory Multiple Myeloma
      • (no location specified)
      Feb 6, 2023